Finasteride-induced myalgia and hyperCKemia

Journal of Clinical Neuromuscular Disease

Volumn 10, Issue 2, 2008, Pages 76-78

  Al Harbi, Talal M ^a   Kagan, Jennifer ^a   Tarnopolsky, Mark A ^b  

^a Division of Neurology   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE KINASE; FINASTERIDE; BIOLOGICAL MARKER; CREATINE KINASE MM; ENZYME INHIBITOR; TESTOSTERONE;

ADULT; ALOPECIA; ARTICLE; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DELTOID MUSCLE; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; HUMAN; ILIOPSOAS MUSCLE; LEG PAIN; MALE; MUSCLE BIOPSY; MUSCLE NECROSIS; MYALGIA; MYOSITIS; PIGMENT DISORDER; PRIORITY JOURNAL; SIDE EFFECT; STAINING; TRICEPS BRACHII MUSCLE; VASTUS MEDIALIS MUSCLE; WEAKNESS; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METABOLISM; MUSCLE DISEASE; PAIN; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTION AND FORECASTING; SKELETAL MUSCLE; UPREGULATION;

ADULT; ALOPECIA; BIOLOGICAL MARKERS; CREATINE KINASE, MM FORM; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MUSCLE, SKELETAL; MUSCULAR DISEASES; PAIN; PREDICTIVE VALUE OF TESTS; TESTOSTERONE; UP-REGULATION;

EID: 64049119609     PISSN: 15220443     EISSN: 15371611     Source Type: Journal    
DOI: 10.1097/CND.0b013e3181873cca     Document Type: Article

References (15)

1. McConnell JD, Wilson JD, George FW, et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1992;74:505-508.
2. Roehrborn CG. Meta-analysis of randomized clinical trials of finasteride. Urology. 1998;51:46-49.
3. Tindall DJ, Rittmaster RS. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol. 2008;179: 1235-1242.
4. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998;39:578-589.
5. McClellan KJ, Markham A. Finasteride: a review of its use in male pattern hair loss. Drugs. 1999;57:111-126.
6. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestos-terone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol. 2002;19:413-425.
7. Wade MS, Sinclair RD. Reversible painful gynaecomastia induced by low dose finasteride (1 mg/day). Australas J Dermatol. 2000;41:55.
8. Lam JS, Romas NA, Lowe FC. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. Urology. 2003;61:354-358.
9. Kaplan SA. 5alpha-reductase inhibitors: what role should they play? Urology. 2001;58:65-70; discussion.
10. Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther. 2007;29:17-25.
11. Haan J, Hollander JM, van Duinen SG, et al. Reversible severe myopathy during treatment with finasteride. Muscle Nerve. 1997;20:502-504.
12. Liu KE, Binsaleh S, Lo KC, Jarvi K. Propecia-induced spermatogenic failure: a report of two cases. Fertil Steril. 2008;90(3):849.e17-849. e19.
13. Persey M, Payne L, Webley M. Finasteride: a steroid-unsparing drug? Rheumatology (Oxford). 1999;38:285.
14. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004;63:742-745.
15. Rittmaster RS. Finasteride. N Engl J Med. 1994;330: 120-125.